BR9708540B1 - formulações injetáveis de avermectinas ou milbemicinas à base de óleo de mamona. - Google Patents

formulações injetáveis de avermectinas ou milbemicinas à base de óleo de mamona.

Info

Publication number
BR9708540B1
BR9708540B1 BRPI9708540-5A BR9708540A BR9708540B1 BR 9708540 B1 BR9708540 B1 BR 9708540B1 BR 9708540 A BR9708540 A BR 9708540A BR 9708540 B1 BR9708540 B1 BR 9708540B1
Authority
BR
Brazil
Prior art keywords
avermectins
castor oil
milbemycin
injectable formulations
pct
Prior art date
Application number
BRPI9708540-5A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9708540A (pt
Inventor
Michael Dr Grosse-Bley
Richard Dr Kujanek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7790774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9708540(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9708540A publication Critical patent/BR9708540A/pt
Publication of BR9708540B1 publication Critical patent/BR9708540B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
BRPI9708540-5A 1996-04-09 1997-03-27 formulações injetáveis de avermectinas ou milbemicinas à base de óleo de mamona. BR9708540B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19613972A DE19613972A1 (de) 1996-04-09 1996-04-09 Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
PCT/EP1997/001569 WO1997037653A1 (de) 1996-04-09 1997-03-27 Injektionsformulierungen von avermectinen und milbemycinen auf basis von rizinusöl

Publications (2)

Publication Number Publication Date
BR9708540A BR9708540A (pt) 1999-08-03
BR9708540B1 true BR9708540B1 (pt) 2010-07-27

Family

ID=7790774

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9708540-5A BR9708540B1 (pt) 1996-04-09 1997-03-27 formulações injetáveis de avermectinas ou milbemicinas à base de óleo de mamona.

Country Status (13)

Country Link
US (1) US6063394A (cg-RX-API-DMAC10.html)
EP (1) EP0896534B1 (cg-RX-API-DMAC10.html)
JP (1) JP4257870B2 (cg-RX-API-DMAC10.html)
CN (1) CN1095662C (cg-RX-API-DMAC10.html)
AT (1) ATE285233T1 (cg-RX-API-DMAC10.html)
AU (1) AU718807B2 (cg-RX-API-DMAC10.html)
BR (1) BR9708540B1 (cg-RX-API-DMAC10.html)
CA (1) CA2251087C (cg-RX-API-DMAC10.html)
DE (2) DE19613972A1 (cg-RX-API-DMAC10.html)
ES (1) ES2235230T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ332224A (cg-RX-API-DMAC10.html)
PT (1) PT896534E (cg-RX-API-DMAC10.html)
WO (1) WO1997037653A1 (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19638045A1 (de) * 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
RS49838B (sr) * 1997-12-03 2008-08-07 Merck& Co. Inc., Injektibilne formulacije dugog dejstva koje sadrže hidrogenisano ricinusovo ulje
US6174540B1 (en) 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
GB9827727D0 (en) 1998-12-16 1999-02-10 Pfizer Ltd Antiparasitic formulations
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
AU781682B2 (en) * 2000-03-20 2005-06-09 Zoetis Services Llc Sustained-release compositions for parenteral administration
US20050009762A1 (en) * 2003-06-06 2005-01-13 Strobel Michael Albert Application of water and organic solvent soluble ivermectin for topical and oral use
CN1275589C (zh) * 2002-05-31 2006-09-20 王玉万 含抗寄生虫药物的缓释注射剂
US7262214B2 (en) 2003-02-26 2007-08-28 Merial Limited 1-N-arylpyrazole derivatives in prevention of arthropod-borne and mosquito-borne diseases
US20050271459A1 (en) * 2004-06-03 2005-12-08 World Wide Stationery Mfg. Co., Ltd. Interlocking ring tip formations for paired ring members of a ring binder mechanism
NZ534939A (en) * 2004-08-26 2007-04-27 Bomac Research Ltd Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility
DE102004053964A1 (de) * 2004-11-09 2006-05-11 Bayer Healthcare Ag Mittel gegen Demodikose
KR20100047311A (ko) * 2007-08-31 2010-05-07 아르키메데스 디벨로프먼트 리미티드 비-수성 약학 조성물
US20100022469A1 (en) * 2008-06-24 2010-01-28 Majid Razzak Anthelminthic formulations
CN102316876B (zh) 2009-02-16 2013-07-17 佐蒂斯有限责任公司 高剂量多拉菌素制剂
CN101773467B (zh) * 2010-01-20 2015-09-09 北京大北农动物保健科技有限责任公司 一种美贝霉素或美贝霉素肟的兽用缓释注射液及制备方法
KR101805087B1 (ko) * 2010-09-16 2017-12-05 주식회사 엘지화학 높은 방부력을 제공하는 오일 주사 제형
WO2013137748A1 (en) * 2012-03-13 2013-09-19 Bayer New Zealand Limited Long acting compositions
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
AU2018385766B2 (en) 2017-12-15 2022-12-01 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
BR112021016196A2 (pt) * 2019-03-01 2021-10-05 Boehringer Ingelheim Animal Health USA Inc. Composições injetáveis de clorsulon, métodos e usos das mesmas
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
US11638714B2 (en) 2020-11-10 2023-05-02 Mountain Valley Md Inc Water dissolvable macrocyclic lactone cyclodextrin complexes
US11077134B1 (en) 2020-11-10 2021-08-03 Mountain Valley Md Inc Water dissolvable macrocyclic lactone cyclodextrin complexes
CA3249951A1 (en) * 2022-01-28 2023-08-03 Rebel Medicine Inc Injectable pharmaceutical compositions for treating pain
CN114642632A (zh) * 2022-02-25 2022-06-21 河北科技大学 一种莫西克汀注射液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4914624A (cg-RX-API-DMAC10.html) * 1972-06-08 1974-02-08
SE434277B (sv) * 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) * 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
OA06863A (fr) * 1980-08-04 1983-02-28 Merck & Co Inc Solubilisation de l'invermectine dans l'eau.
NZ210505A (en) * 1983-12-22 1988-06-30 Merck & Co Inc Parasiticidal compositions containing avermectin or milbemycin derivatives
DE3727648A1 (de) * 1987-08-19 1989-03-02 Bayer Ag Neue avermectin derivate, verfahren zu ihrer herstellung und ihre verwendung
US5510117A (en) * 1989-03-09 1996-04-23 Micro-Pak, Inc. Entrapment vehicle and method
DK0393890T3 (da) * 1989-04-11 1992-09-28 Pfizer Injicerbart præparat indeholdende 25-cyclohexyl-avermectin B1
NZ234802A (en) * 1989-08-14 1992-11-25 Merck & Co Inc Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals
EP0525307B1 (en) * 1991-07-23 1996-03-06 American Cyanamid Company Stable compositions for parenteral administration and their use
ES2131515T3 (es) * 1991-09-30 1999-08-01 Merck & Co Inc Formulados inyectables de accion prolongada que contienen aceite de ricino hidrogenado.
WO1994008566A1 (en) * 1992-10-21 1994-04-28 Micro Vesicular Systems, Inc. Entrapment vehicle and method

Also Published As

Publication number Publication date
PT896534E (pt) 2005-04-29
DE59712134D1 (de) 2005-01-27
WO1997037653A1 (de) 1997-10-16
US6063394A (en) 2000-05-16
ATE285233T1 (de) 2005-01-15
AU718807B2 (en) 2000-04-20
AU2506697A (en) 1997-10-29
CN1215331A (zh) 1999-04-28
JP4257870B2 (ja) 2009-04-22
JP2000508301A (ja) 2000-07-04
CA2251087C (en) 2008-01-15
CA2251087A1 (en) 1997-10-16
DE19613972A1 (de) 1997-10-16
EP0896534B1 (de) 2004-12-22
ES2235230T3 (es) 2005-07-01
NZ332224A (en) 2000-06-23
CN1095662C (zh) 2002-12-11
HK1019404A1 (en) 2000-02-11
EP0896534A1 (de) 1999-02-17
BR9708540A (pt) 1999-08-03

Similar Documents

Publication Publication Date Title
BR9708540B1 (pt) formulações injetáveis de avermectinas ou milbemicinas à base de óleo de mamona.
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
YU15299A (sh) Farmaceutski sastavi
NO2005009I2 (no) Emselex-darifenacin. Iupac-navn: (S)-2-ä1-Ä2-(2,3 -dihydrobenzofuran-5-yl)etylÜ-3-pyrrolidinylü-2,2-difenylacetamid
ATE228845T1 (de) Injektionsformulierungen von avermectinen und milbemycinen
DE69917663D1 (de) 2-methyl-thieno-benzodiazepin-formulierung
ES2162929T3 (es) Procedimiento para la preparacion de 2-(1-azabiciclo(2.2.2)oct-3-il)-2,4,5,6-tetrahidro-1h-benz(de)isoquinolin-1-ona y producto intermediario.
ATE251457T1 (de) Substituierte 1,2,3,4-tetrahydro-2- dibenzofuranamine und 2- aminocyclohepta(b)benzofurane
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
ES2175356T3 (es) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4 fluorofenil)et il[-4- piperidinmetanol en el tratamiento de trastornos depresivos y trastornos bipolares.
ATE215084T1 (de) Imidazopyridin-azolidinone
PT938306E (pt) Composicoes antimalaricas contendo derivados de ciclopenteno-1,2,4-trioxano fundidos em cis
PT1011329E (pt) Paclitaxeis de 7-metiltio-oxometilo e 7-metiltiodioxometilo
PL322999A1 (en) Phospholipidic composition and and method of obtaining same
ES2165020T3 (es) Monohidrato de famciclovir.
DK0896534T3 (da) Injektionsformuleringer af avermectiner og milbemyciner på basis af ricinusolie
CA2096345A1 (en) Avermectins and milbemycins to treat parasitic in dogs
ES2141923T3 (es) Uso hipocolesterolemico, antiaterosclerotico e hipotrigliceridemico de derivados aminoacetilmercapto.
Barrett Relocation of the office of the Journal of Hospital Infection
BR0212114A (pt) Métodos e composições de fluridona suportada
AU4669499A (en) New therapeutic use of pkb (proteine kinase b) enhancers
IT1292254B1 (it) Apparecchio idrosanitario, particolarmente per infermi e portatori di handicap.
FR2708918B1 (fr) Le cylindre aérien des villes destiné à la circulation humaine.
IT1303270B1 (it) Piedino regolabile di sostegno per armadi e simili.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE PATENTE COM BASE NOS ARTIGOS 8, 11 E 13 DA LPI NO 9.279 DE 14/05/1996

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAYER ANIMAL HEALTH GMBH (DE)

Free format text: TRANSFERIDO DE: BAYER AKTIENGESELLSCHAFT

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/07/2010, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061190/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132255-93.2013.4.02.51011 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: BAYER AKTIENGESELLSCHAFT, BAYER ANIMAL HEALTH GMBH, BAYER CROPSCIENCE AG.

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)